Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
Our findings provided the support for use of MRD-CR classified at a 10<sup>-5</sup> threshold at either 9 or 12 months after starting of the treatment, as an intermediate end point to support accelerated approvals, in future trials in NDTE patients, NDTinE patients, and patients with RRMM.
Authors
- Pieter Sonneveld (ORCID: https://orcid.org/0000-0002-0808-2237)
- Mattia D’Agostino (ORCID: https://orcid.org/0000-0002-1711-6996)
- Dirk Hose (ORCID: https://orcid.org/0000-0003-0806-5223)
- Anja Seckinger (ORCID: https://orcid.org/0000-0002-2771-712X)
- Jesús F. San Miguel (ORCID: https://orcid.org/0000-0002-9183-4857)
- Stefania Oliva (ORCID: https://orcid.org/0000-0002-3084-180X)
- Brian G.M. Durie (ORCID: https://orcid.org/0000-0002-9883-3769)
- Shaji Kunnathu Kumar (ORCID: https://orcid.org/0000-0001-5392-9284)
- Natalie Dimier (ORCID: https://orcid.org/0000-0002-8537-4962)
- Kenneth Carl Anderson (ORCID: https://orcid.org/0000-0002-6418-0886)
- Nikhil C. Munshi (ORCID: https://orcid.org/0000-0002-7344-9795)
- Qian Shi (ORCID: https://orcid.org/0000-0002-4640-8832)
- Levi Pederson (ORCID: https://orcid.org/0000-0001-5902-8882)
- Hartmut Goldschmidt (ORCID: https://orcid.org/0000-0003-0961-0035)
- Bruno Paiva (ORCID: https://orcid.org/0000-0003-1977-3815)
- Roger G. Owen
- Philip L. McCarthy (ORCID: https://orcid.org/0000-0002-9577-3879)
- Thomas J. Prior (ORCID: https://orcid.org/0000-0001-5220-7730)
- Reshma Patel
- Jesse G. Dixon (ORCID: https://orcid.org/0000-0002-6612-1564)
- Jordan Mark Schecter (ORCID: https://orcid.org/0000-0001-5849-0987)
- Alberto Órfão (ORCID: https://orcid.org/0000-0002-0007-7230)
- Philippe Moreau (ORCID: https://orcid.org/0000-0003-1780-8746)
- Blake Bartlett
- Ela Talpes
Institutions
- Cedars-Sinai Medical Center (US)
- Roswell Park Comprehensive Cancer Center (US)
- Amgen (United States) (US)
- Johnson & Johnson (United States) (US)
- Vrije Universiteit Brussel (BE)
- Harvard University (US)
- Universidad de Salamanca (ES)
- Heidelberg University (DE)
- St James's University Hospital (GB)
- University Hospital Heidelberg (DE)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Roche (United Kingdom) (GB)
- Dana-Farber Cancer Institute (US)
- Mayo Clinic in Arizona (US)
- Clinica Universidad de Navarra (ES)
- Johnson & Johnson (United Kingdom) (GB)
- Mayo Clinic in Florida (US)
- Erasmus MC Cancer Institute (NL)
- University of Turin (IT)
- Universidad de Navarra (ES)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1200/jco-24-02020
- Citations
- 29
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 51.33